SuperworthScholar Rock market cap SRRK
Share price times shares outstanding: what the whole company sells for, since 2018.
- Today, Oct 23, 2026
- $5.1B
- Highest close in our data
- $7B
- Aug 2026
Scholar Rock is worth $5.1B at the close on Oct 23, 2026, at $41.49 a share.
That is up 77% over the last year and up 458% over five years.
Its highest close in our data was $7B in Aug 2026.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $5.1B | $4.3B | $7B | +8% |
| 2025 | $4.7B | $2.5B | $4.8B | +12% |
| 2024 | $4.2B | $593.8M | $4.2B | +207% |
| 2023 | $1.4B | $332.7M | $1.4B | +190% |
| 2022 | $467.6M | $173.7M | $751.7M | −46% |
| 2021 | $872.1M | $872.1M | $2.2B | −47% |
| 2020 | $1.6B | $285.8M | $1.7B | +323% |
| 2019 | $386.1M | $227M | $578.4M | −28% |
| 2018 | $538.6M | $363M | $662.5M | n/a |
Against its peers
Companies in Biotechnology nearest Scholar Rock's size, closest first, today.
| Company | Market cap |
|---|---|
| SRRKScholar Rock | $5.1B |
| KRYSKrystal Biotech | $9.2B |
| RGENRepligen | $10B |
| ADMAAdma Biologics | $2.4B |
| TECHBIO-TECHNE | $11.4B |
| VCELVericel | $2.2B |
| HALOHalozyme Therapeutics | $14.3B |
| NBIXNeurocrine Biosciences | $14.5B |
| EXELExelixis | $16B |
| INCYIncyte | $23.5B |
| UTHRUnited Therapeutics | $25.2B |
| Peer median | $12.8B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Scholar Rock
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.